The lack of imaging biomarkers is a key obstacle to the development of treatment for progressive multiple sclerosis. While diffusion MRI is a promising biomarker, variability among scanners may limit its use. We examine site-related variability among multiple sclerosis patients to inform the design of multicenter trials.
This abstract and the presentation materials are available to members only; a login is required.